The Global Infertility Testing Market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user. The report provides data for 2015 to 2024, 2016 being the current year while 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Access Full Report: http://databridgemarketresearch.com/reports/global-infertility-testing-market/
The global infertility testing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The Merck KGaA dominated the infertility testing market accounting for a highest market share in 2016, followed by Procter & Gamble and bioMérieux SA. Other players in this market include Babystart Ltd, Biozhena Corporation, Quidel Corporation, Alere Inc., SPD Swiss Precision Diagnostics GmBH, Proctor & Gamble, SCSA Diagnostics, Inc., among others.
Founded in 1668 and headquartered in Darmstadt, Germany. Merck KGaA, is a leading science and technology company in healthcare, life science and performance materials. It operates as a EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business. The healthcare business design and develop medicines and intelligent devices that provide ongoing care for patients beyond the treatment. The life science business engaged in drug discovery and development to manufacturing and diagnostics. The performance materials develop specialty chemicals and high-tech materials for particularly demanding applications.
Sigma Aldrich operates as a subsidiary of Merck KGaA, which offers the fertility test kit.
The healthcare business segment has the enhanced portfolio fertility technologies.
Merck KGaA has 50,000 employees in 66 countries across the globe.
Proctor & Gamble.:
Founded in 1837 and headquartered in Ohio, US. Proctor & Gamble is Consumer Goods Corporation. It has five segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. P&G Healthcare holds nearly 20% global market share.
Procter & Gamble has acquired a number of other companies that diversified its product line and significantly increased profits. Some of its acquisition include Folgers Coffee, Norwich Eaton Pharmaceuticals, Richardson-Vicks, Noxell (Noxzema), Shulton's Old Spice, Max Factor, the Iams Company, and others. P&G operates in approximately 70 countries worldwide. It is present in North America, Europe, Latin America, Asia Pacific, Greater China and India, Middle East and Africa (IMEA).
In October 2017, P&G unveiled its new innovation in ovulation testing that pairs the accuracy of the Clearblue Ovulation Test, now with the app. The Clearblue Connected app will remind users when to test, display a user’s daily test results and let the user record details also.
Founded in 1963 and headquartered in Marcy-l'Étoile, France. bioMérieux SA provide diagnostic solutions like reagents, instruments and software to customers. bioMérieux SA operates in agri-food, cosmetics and pharmaceutical industries. BioMérieux provides VIDAS Fertility panel under immunoassay emergency diagnostic patient management segment.
bioMérieux SA is present in more than 150 countries through 42 subsidiaries and a large network of distributors. The company is present in the US, Asia pacific and EMEA region.
Global Fertility Testing Devices Market – Industry Trends - Forecast to 2026
North America Fertility Testing Devices Market - Industry Trends and Forecast to 2024
Asia-Pacific fertility Testing Devices Market – Industry Trends and Forecast to 2024
Europe Fertility Testing Devices Market – Industry Trends and Forecast to 2024